鹜芪口服液联合化疗对Lewis肺癌小鼠增效减毒作用研究

许志 谢梦洲 许必祥 刘雪辉 贺静 王筱宇

〔摘要〕 目的 观察鹜芪口服液联合化疗对Lewis肺癌小鼠化疗效果的影响。方法 将腋下接种Lewis肺癌细胞小鼠随机分为6组，分别为模型对照组、化疗组、化疗+贞芪扶正颗粒组（贞芪扶正组）、化疗+鹜芪口服液低剂量组（鹜芪低剂量组）、化疗+鹜芪口服液中剂量组（鹜芪中剂量组）、化疗+鹜芪口服液高剂量组（鹜芪高剂量组），同时设立正常对照组，各组按照给药方法进行连续给药21 d。给药后每隔3 天，对Lewis肺癌小鼠的肿瘤的长径和短径进行测定、给藥21 d后对血液中炎性细胞WBC、Neu、Lym、Mon、Eos、Bas的数目进行测定，并对胸腺、脾脏、胃进行组织病理学检查。结果 与化疗组比较，鹜芪低、中剂量组小鼠给药第15～21天肿瘤体积减少;鹜芪高剂量组小鼠给药第21天肿瘤体积明显减少（P<0.05）。与化疗组比较，鹜芪低、中、高剂量组小鼠血液中WBC、Neu、Mon、Eos数目明显减少（P<0.05或P<0.01）。鹜芪口服液联合化疗能明显改善小鼠脾脏红髓造血情况，改善胸腺萎缩和局灶性纤维化。结论 鹜芪口服液联合化疗用药对Lewis肺癌荷瘤小鼠具有明显的增效减毒作用。

〔关键词〕 鹜芪口服液;化疗;肿瘤体积;增效减毒;炎性细胞

〔中图分类号〕R285.5       〔文献标志码〕A       〔文章编号〕doi：10.3969/j.issn.1674-070X.2021.05.008

The Study About Effect-enhancing and Toxicity-reducing Effects of Wuqi Oral Liquid

Combined with Chemotherapy in Mice with Lewis Lung Cancer

XU Zhi1， XIE Mengzhou2*， XU Bixiang1， LIU Xuehui1， HE Jing1， WANG Xiaoyu1

（1. Hunan Tianjin Pharmaceutical Co.， Ltd. Changsha， Hunan 410205， China; 2. Hunan University of

Chinese Medicine， Changsha， Hunan 410208， China）

〔Abstract〕 Objective To observe the effect of Wuqi Oral Liquid combined with chemotherapy on the chemotherapy effect of Lewis lung cancer mice. Methods Mice inoculated with Lewis lung cancer cells under the armpits were randomly divided into 6 groups： model control group， chemotherapy group， chemotherapy+Zhenqi Fuzheng granule group （Zhenqi Fuzheng group）， chemotherapy+Wuqi Oral Liquid low-dose group （Wuqi low-dose group）， chemotherapy+Wuqi Oral Liquid medium-dose group （Wuqi medium-dose group）， chemotherapy+Wuqi Oral Liquid high-dose group （Wuqi high-dose group）， and a normal control group was set up at the same time， each group was dealt with the administration method. The administration of drug was continued for 21 days. The long and short diameters of the tumors in Lewis lung cancer mice were measured every 3 days after the administration. After 21 days of administration， the blood inflammatory cells WBC， Neu， Lym， Mon， Eos and Bas was measured， and histopathological examination was performed on the thymus， spleen， and stomach. Results Compared with the chemotherapy group， the volume of tumors in mice of Wuqi low and medium doses group decreased from 15 to 21 days after administration; the volume of tumors in mice of Wuqi high-dose group was significantly reduced on the 21st day （P<0.05）. Compared with the chemotherapy group， the number of WBC， Neu， Mon， Eos inflammatory cells in the blood of mice of Wuqi low， medium and high doses group significantly reduced （P<0.05 or P<0.01）. Wuqi Oral Liquid combined with chemotherapy can significantly improve the hematopoiesis of the red marrow of the mouse spleen， and improve thymic atrophy and focal fibrosis. Conclusion Wuqi Oral Liquid combined with chemotherapy has a significant effect of increasing efficacy and reducing toxicity in mice with Lewis lung cancer.

〔Keywords〕 Wuqi Oral Liquid; chemotherapy; tumor volume; effect-enhancing and toxicity-reducing; inflammatory cells

肿瘤化疗是目前癌症治疗的主要手段之一，化疗药物进入机体后广泛分布于肝脏、肾脏、血液等组织器官，并主要由肝脏、肾脏代谢和排出[1]。因此，化療药物在杀灭肿瘤细胞的同时，也不可避免地损伤了机体正常的细胞，表现出一系列化疗的不良反应，如免疫功能下降、骨髓抑制、肝脏毒性、肾脏毒性、消化道障碍等[2-4]。中医学认为化疗属于以毒攻毒的治法[5]，最易伤人正气，而表现出机体虚弱等症状。在全球癌症（GLOBOCAN）2018数据库中，每年全球估计有209万新病例，176万人死于肺癌[6]。鹜芪口服液为湖南天劲制药有限责任公司独家品种，以鸭为君药入药，功效为养阴益气、补虚扶正，能够提升机体正气。……